Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

841 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis.
Bouchahda M, Macarulla T, Liedo G, Lévi F, Elez ME, Paule B, Karaboué A, Artru P, Tabernero J, Machover D, Innominato P, Goldschmidt E, Bonnet D, Ducreux M, Castagne V, Guimbaud R. Bouchahda M, et al. Among authors: tabernero j. Med Oncol. 2011 Dec;28 Suppl 1:S253-8. doi: 10.1007/s12032-010-9716-8. Epub 2010 Nov 5. Med Oncol. 2011. PMID: 21053102
Monoclonal antibodies in the treatment of advanced colorectal cancer.
Capdevila J, Saura C, Macarulla T, Casado E, Ramos FJ, Tabernero J. Capdevila J, et al. Among authors: tabernero j. Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S24-34. doi: 10.1016/j.ejso.2007.09.025. Epub 2007 Nov 5. Eur J Surg Oncol. 2007. PMID: 17981431 Review.
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.
Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Roselló S, Liebscher S, Kisker O, Macarulla T, Baselga J, Cervantes A. Tabernero J, et al. Ann Oncol. 2010 Jul;21(7):1537-1545. doi: 10.1093/annonc/mdp549. Epub 2009 Nov 25. Ann Oncol. 2010. PMID: 19940007 Free article. Clinical Trial.
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F. Macarulla T, et al. Among authors: tabernero j. Br J Cancer. 2015 Jun 9;112(12):1874-81. doi: 10.1038/bjc.2015.144. Epub 2015 May 19. Br J Cancer. 2015. PMID: 25989270 Free PMC article. Clinical Trial.
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. Van Cutsem E, et al. Among authors: tabernero j. Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5. Ann Oncol. 2016. PMID: 27380959 Free article.
841 results